IP Library Granted Patent US 8,088,406
Granted Patent B2
US 8,088,406 · App. 11/633,804 · Granted Jan 3, 2012

Pioneer projectile drug delivery technology

Assignee: Glide Pharmaceutical Technologies Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,406
App. No.
11/633,804
Granted
Jan 3, 2012
Kind
B2
Abstract

The invention relates to a novel drug delivery technology. More particularly the invention relates to a method of delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient; to a throwaway or reusable device for delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient in a manner as set out by the method; to a pioneer projectile for use in said method; to formulations for use in said method and to an injectate comprising a pioneer projectile and formulation. It also relates to a disposable component containing either a pioneer projectile or an injectate. The invention also relates to a throwaway or reusable device for delivering at least one therapeutic compound, or a formulation comprising the at least one therapeutic compound (hereafter drug) to a patient, and a method for administering a drug to a patient using said device. It also relates to a packaged drug for use with said device.

Claims (13)

1. A method of delivering at least one therapeutic compound or a formulation containing at least one therapeutic compound to a human or animal in the form of a needleless injection comprising:

penetrating the skin with a water soluble, lipid soluble or otherwise biodegradable pioneer projectile having a diameter of less than 3 mm which is left in the human or animal; and

introducing behind the pioneer projectile, the at least one therapeutic compound or the formulation containing the at least one therapeutic compound, which at least one therapeutic compound or the formulation containing the at least one therapeutic compound is provided and delivered in a contained state.

2. A method as claimed in claim 1 wherein the pioneer projectile is water soluble.

3. A method as claimed in claim 1 wherein the pioneer projectile is independent of the at least one therapeutic compound or the formulation containing the at least one therapeutic compound.

4. A method as claimed in claim 1 wherein the pioneer projectile is independent of yet forms an integral part of the at least one therapeutic compound or the formulation containing the at least one therapeutic compound.

5. A method as claimed in claim 4 wherein the pioneer projectile forms a head to the at least one therapeutic compound or the formulation containing the at least one therapeutic compound.

6. A method as claimed in claim 1 wherein the at least one therapeutic compound or the formulation containing the at least one therapeutic compound is provided in a liquid form which is contained in a biodegradable membrane.

7. A method as claimed in claim 1 wherein the at least one therapeutic compound or the formulation containing the at least one therapeutic compound is provided in a solid form.

8. A method as claimed in claim 1 wherein the at least one therapeutic compound or the formulation containing the at least one therapeutic compound is provided as a semi solid or a gel or a paste.

9. A method as claimed in claim 7 wherein the solid form comprises crystals, particles, granules, beads, rods, discs or a combination thereof.

10. A method as claimed in claim 1 in which the skin is penetrated and the at least one therapeutic compound or the formulation containing the at least one therapeutic compound is administered at a low velocity of less than 100 m/s.

11. A method as claimed in claim 10 wherein the velocity is less than 10 m/s.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2019
From: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
To: ENESI PHARMA LIMITED
Reel/Frame 049811/0014 →
Continuity (2)
Continuation 10238415 · Sep 10, 2002
Related Publication 20070275044A1 · Nov 29, 2007